The North America Insulin Syringes Market would witness market growth of 3.0% CAGR during the forecast period (2021-2027).
Diabetic people are more susceptible to COVID-19 infection and hence seek good glycemic management. As a result of the widespread use of insulin syringes and continuous glucose monitoring devices, diabetes can now be closely monitored and managed. In addition, the firms are attempting to provide crucial healthcare insulin syringes, pumps, and other items through a variety of channels, including an internet portal, emergency medical stores and hospital pharmacies.
For example, Ely Lilly developed the Diabetes Solution Center initiative to give free insulin therapy to financially disadvantaged insulin users. As a result, COVID-19's overall influence on the insulin syringe industry is good.
Diabetes affects about 463 million persons aged 20 to 79 years in 2019, with the number anticipated to climb to 700 million by 2045. Diabetes claimed the lives of 4.2 million people worldwide, with 79 percent of diabetic adults residing in low- and middle-income nations. As per the American Diabetes Association, the cost of healthcare in the United States has grown by 26% in the previous five years due to rising diabetes rates.
The US market dominated the North America Insulin Syringes Market by Country 2020, and would continue to be a dominant market till 2027; thereby, achieving a market value of $514.8 million by 2027. The Canada market is experiencing a CAGR of 5.4% during (2021 - 2027). Additionally, The Mexico market would witness a CAGR of 4.4% during (2021 - 2027).
Based on Disease, the market is segmented into Type 2 Diabetes and Type 1 Diabetes. Based on Syringe Size, the market is segmented into 3/10 CC Syringe (0.3ml), 1/2 CC Syringe (0.5ml), 1CC Syringe (1ml) and Others. Based on End User, the market is segmented into Hospitals & Clinics, Homecare Settings, and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Global Insulin Syringes Market is Estimated to reach $2.1 Billion by 2027, at a CAGR of 4.5%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Hindustan Syringes & Medical Devices Ltd., Novo Nordisk A/S, Biocon Limited, Eli Lilly and Company, Abbott Laboratories, Becton, Dickinson and Company, Cardinal Health, Inc., Medline Industries, Inc., Terumo Corporation, and Nipro Corporation.
By Disease
By Syringe Size
By End User
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 